IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10434169 B1

PDFFull Text
Date of Patent:
Oct. 08, 2019

Filed:

Feb. 08, 2018

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

Applicants:

Sillajen Biotherapeutics, Inc., San Francisco, CA (US);

Sillajen, Inc., Busan, KR;

Inventors:

David Kirn, Mill Valley, CA (US);

John Bell, Ottawa, CA;

Caroline Breitbach, San Francisco, CA (US);

Anne Moon, San Francisco, CA (US);

Tae-Ho Hwang, Busan, KR;

Yu Kyoung Lee, Busan, KR;

Mi-kyung Kim, Busan, KR;

Assignees:

SILLAJEN, INC, Busan, KR;

SILLAJEN BIOTHERAPEUTICS, INC., San Francisco, CA (US);

Attorneys:

Christopher M. Cabral

Polsinelli PC

Primary Examiner:

Sean E Aeder

Int. Cl.
CPC ...
A61K 39/285 (2006.01); A61K 39/00 (2006.01); C07K 16/30 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 35/763 (2015.01); A61K 35/768 (2015.01); A61K 35/26 (2015.01); A61K 39/12 (2006.01); A61K 39/125 (2006.01); A61K 39/145 (2006.01); A61K 39/165 (2006.01); A61K 39/17 (2006.01); A61K 39/205 (2006.01); A61K 39/235 (2006.01); A61K 39/245 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/18 (2006.01); C12N 7/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 39/285 (2013.01); A61K 35/26 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 35/763 (2013.01); A61K 35/768 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/125 (2013.01); A61K 39/145 (2013.01); A61K 39/165 (2013.01); A61K 39/17 (2013.01); A61K 39/205 (2013.01); A61K 39/235 (2013.01); A61K 39/245 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C12N 7/00 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55522 (2013.01); C07K 2317/14 (2013.01); C07K 2317/734 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/16632 (2013.01); C12N 2710/16634 (2013.01); C12N 2710/24034 (2013.01); C12N 2710/24132 (2013.01); C12N 2720/12232 (2013.01); C12N 2750/14034 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/18134 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18734 (2013.01); C12N 2760/20034 (2013.01); C12N 2760/20232 (2013.01); C12N 2770/32034 (2013.01); C12N 2770/32334 (2013.01); C12N 2770/36034 (2013.01);
Abstract

The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Find Patent Forward Citations

Loading…